Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Nebula Research & Development LLC

Nebula Research & Development LLC raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 95.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,804 shares of the company’s stock after acquiring an additional 9,697 shares during the period. Nebula Research & Development LLC’s holdings in Day One Biopharmaceuticals were worth $251,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd acquired a new stake in Day One Biopharmaceuticals in the 4th quarter valued at approximately $31,000. Tower Research Capital LLC TRC raised its holdings in shares of Day One Biopharmaceuticals by 911.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after buying an additional 9,603 shares during the period. E Fund Management Co. Ltd. acquired a new position in Day One Biopharmaceuticals during the 4th quarter worth about $143,000. KLP Kapitalforvaltning AS purchased a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $150,000. Finally, Optimize Financial Inc purchased a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $196,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Trading Down 2.1 %

Shares of DAWN opened at $7.62 on Friday. The firm has a market capitalization of $772.32 million, a price-to-earnings ratio of -7.40 and a beta of -1.24. The firm’s fifty day simple moving average is $8.00 and its 200-day simple moving average is $11.43. Day One Biopharmaceuticals, Inc. has a twelve month low of $6.41 and a twelve month high of $18.00.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. On average, analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now directly owns 39,602 shares of the company’s stock, valued at $473,639.92. This trade represents a 10.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. This trade represents a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,064 shares of company stock valued at $251,925. Corporate insiders own 6.20% of the company’s stock.

Wall Street Analyst Weigh In

DAWN has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush restated an “outperform” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Finally, Bank of America decreased their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $32.29.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.